Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-24
2011-05-24
Loewe, Sun Jae Y (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S444000, C548S246000, C549S007000
Reexamination Certificate
active
07947720
ABSTRACT:
There are disclosed compounds of the formulaor a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
REFERENCES:
patent: 4170588 (1979-10-01), Hegenberg et al.
patent: 4639523 (1987-01-01), Nohara et al.
patent: 5206252 (1993-04-01), Butera et al.
patent: 5354763 (1994-10-01), Butera et al.
patent: 5397790 (1995-03-01), Butera et al.
patent: 5401753 (1995-03-01), Butera et al.
patent: 5403853 (1995-04-01), Butera et al.
patent: 5466712 (1995-11-01), Butera et al.
patent: 5506252 (1996-04-01), Butera et al.
patent: 5532245 (1996-07-01), Butera et al.
patent: 5840764 (1998-11-01), Quagliato et al.
patent: 6174905 (2001-01-01), Suzuki et al.
patent: 6211220 (2001-04-01), Pamukeu et al.
patent: 6300325 (2001-10-01), Widdowson et al.
patent: 6376555 (2002-04-01), Butera et al.
patent: 6420396 (2002-07-01), Albers et al.
patent: 6878709 (2005-04-01), Taveras et al.
patent: 7132445 (2006-11-01), Taveras et al.
patent: 2001/0018447 (2001-08-01), Widdowson et al.
patent: 2003/0080053 (2003-05-01), Held et al.
patent: 2003/0204085 (2003-10-01), Taveras et al.
patent: 2004/0034229 (2004-02-01), Taveras et al.
patent: 2004/0053953 (2004-03-01), Taveras et al.
patent: 2004/0097547 (2004-05-01), Taveras et al.
patent: 2004/0106794 (2004-06-01), Taveras et al.
patent: 2004/0186142 (2004-09-01), Taveras et al.
patent: 2007/0021494 (2007-01-01), Taveras et al.
patent: 2008/0190441 (2008-08-01), Vecchiola
patent: 33 09 655 (1984-09-01), None
patent: 0 275 997 (1988-07-01), None
patent: 0 376 079 (1990-07-01), None
patent: 0 796 243 (1999-01-01), None
patent: 1186096 (1970-04-01), None
patent: WO 94/29277 (1994-12-01), None
patent: WO 95/14005 (1995-05-01), None
patent: WO 96/14300 (1996-05-01), None
patent: WO 96/15103 (1996-05-01), None
patent: WO 98/33763 (1998-08-01), None
patent: WO 99/61410 (1999-12-01), None
patent: WO 00/20378 (2000-04-01), None
patent: WO 00/21927 (2000-04-01), None
patent: WO 00/35855 (2000-06-01), None
patent: WO 00/35864 (2000-06-01), None
patent: WO 00/73260 (2000-12-01), None
patent: WO 01/29000 (2001-04-01), None
patent: WO 01/64208 (2001-09-01), None
patent: WO 01/64691 (2001-09-01), None
patent: WO 01/68569 (2001-09-01), None
patent: WO 01/92202 (2001-12-01), None
patent: WO 02/083624 (2002-04-01), None
patent: WO 02/067919 (2002-09-01), None
patent: WO 02/076926 (2002-10-01), None
patent: WO 02/083624 (2002-10-01), None
patent: WO 03/080053 (2003-10-01), None
patent: WO 2005/075447 (2005-08-01), None
patent: WO 02/057230 (2007-07-01), None
Chawla et al., “Challenges in Polymorphism of Pharmaceuticals”, CRIPS vol. 5, No. 1, Jan.-Mar. 2004 (4 Pages.
Newman et al., “Solid-state analysis of the active pharmaceutical ingredient in drug products”, DDT vol. 8, No. 19, Oct. 2003, p. 898-905.
esp@cenet Document, “1,2,5-Thiadiazole-1-oxides and 1,1-dioxides, process for their preparation and their use as medicaments” (for DE3309655 which is attached to said esp document), 1991.
Chemical Abstract 66:18527 for Maahs, Guenther, et al., “Syntheses and derivatives of squaric acid,”Angewandte Chemie78(20):927-31 (1966) (which is attached to said abstract).
Chemical Abstract 87:134383 for Augustin Manfred, et al., “Disubstitution in 2,3-dichloromaleimides”Zeitschrift FuerChemie 17(6):215-216 (1977) (which is attached to said abstract).
Chemical Abstract No. 87:151727 for Ehrhardt, Heinz, et al., “Amides and thioamides of squaric acid: syntheses and reactions,”Chemische Berichte110(7):2506-23 (1977) (which is attached to said abstract).
Chemical Abstract 104:129517 for Gruenefeld, Johann, et al., “Reactions of squaric acid with carbodiimides,”Archiv der Pharmazie318(12):1062-70 (1985) (which is attached to said abstract).
Chemical Abstract No. 122:160745 for Tillack, Annegret, et al., “Assymmetric catalysis. IV. Hydrosilylation of acetophenone with pyrroline-2,5-dione modified [Rh(COD)C1]2 catalyst,”Journal of Organometallic Chemistry482:84-91 (1994) (which is attached to said abstract).
Chemical Abstract No. 125:300482 for Chen, Yizhao, et al., “Reaction of dibutyl oxosquarate with aromatic primary amines,”Sichuan Daxue Xuebao, Ziran Kexueban33(2):182-186 (1996) (which is attached to said abstract).
Chemical Abstract No. 130:222994 for Chen, Yi-Zhao, et al., “Synthesis of asymmetric aryl-substituted amides of squaric acid and asymmetric isosquarylium amides,”Hechen Huaxue6(4):383-392 (1998) (which is attached to said abstract).
Butera, John A., et al., “Design and SAR of Novel Potassium Channel Openers Targeted for Urge Urinary Incontinence. 1.N-Cyanoguanidine Bioisosteres Possessing in Vivo Bladder Selectivity,”J. Med. Chem. 43:1187-1202 (2000).
Davis, Peter D., et al., “Inhibitors of protein kinase C 1. 2,3-Bisarylmaleimides,”J. Med. Chem. 35:177-184 (1992).
Hanaineh-Abdelnour, Leila, et al., “Some synthetic applications of 2,3-Dichloro-N-phenylmaleimide: A Novel Synthesis of 2-Phenylpyrrolo[3,4-b]quinoxaline-1,3-diones. I,”Tetrahedron55:11859-11870 (1999).
Neuse, Eberhard W., et al., “Poly(squaryl amides)”Polymer15:339-45 (1974).
Zhou, Hai-Bing, et al., “Design, synthesis and structure of new chiral squaric acid monoaminoalcohls and diaminoalcohols and their use as catalysts in asymmetric reduction of ketones and diketones,”Tetrahedron57:9325-9333 (2001).
PCT International Search Report dated Aug. 2, 2002 for related PCT Application No. PCT/US02/12681.
PCT International Search Report dated Nov. 17, 2003 for related PCT Application No. PCT/US03/23722.
PCT International Search Report dated Nov. 17, 2003 for related PCT Application No. PCT/US03/23785.
Communication pursuant to Article 96(2) EPC for Application No. 02 739 172.1-2101 dated Jul. 13, 2004.
Communication pursuant to Article 96(2) EPC for Application No. 03 772 075.2-2101 dated Nov. 14, 2005.
Patent Abstracts of Japan, vol. 018, No. 361 (c-1222), Jul. 7, 1994 and JP 06 092915A, Apr. 5 1994 abstract.
Translation for Japanese 6-92915 (see above Non-Patent document “CP”), 2010.
Aki Cynthia J.
Baldwin John J.
Biju Purakkattle J.
Bond Richard W.
Chao Jianhua
Jeanette Henry C.
Loewe Sun Jae Y
Meade Eric A.
Pharmacopeia Drug Discovery
Schering Corporation
LandOfFree
3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2676472